1. Puri P. Acute Exacerbation of Chronic Hepatitis B: The Dilemma of Differentiation from Acute Viral Hepatitis B. Journal of Clinical and Experimental Hepatology. 2013; 3 (4): 301-12.
2. Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, et al. Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis. PLoS ONE. 2012; 7 (9): e44611.
3. Vahid T, Alavian SM, Kabir A, Kafaee J, Yektaparast B. Hepatitis B Prevalence and Risk Factors in Blood Donors in Ghazvin, IR.Iran. Hepat Mon. 2005; 5 (4): 117-22.
4. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. Journal of Gastrointestinal and Liver Diseases. 2007; 16 (4): 403.
5. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985; 317 (6037): 489-95.
6. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annual review of immunology. 2007; 25: 71-99.
7. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996; 4 (1): 25-36.
8. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proceedings of the National Academy of Sciences. 2002; 99 (24): 15661-8.
9. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999; 354 (9196): 2119-24.
10. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. The Journal of infectious diseases. 2001; 184 (1): 16-21.
11. Par a, Par G, Tornai I, Szalay F, Varszegi D, Frater E, et al. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC research notes. 2014; 7: 12.
12. Bagheri V, Askari A, Arababadi MK, Kennedy D. Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection? Human Immunology. 2014; 75 (6): 549-54.
13. Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. International journal of cancer Journal international du cancer. 2011; 128 (7): 1692-6.
14. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12 / interleukin-12-receptor system: role in normal and pathologic immune responses. Annual review of immunology. 1998; 16: 495-521.
15. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine & growth factor reviews. 2003; 14 (5): 361-8.
16. Robinson RT. IL12Rbeta1: the cytokine receptor that we used to know. Cytokine. 2015; 71 (2): 348-59.
17. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988; 16 (3): 1215.
18. Tong Hv, Thomas Bock C, Velavan TP. Genetic insights on host and hepatitis B virus in liver diseases. Mutation Research / Reviews in Mutation Research. 2014; 762 (0): 65-75.
19. Chisari FV. Cytotoxic T cells and viral hepatitis. Journal of Clinical Investigation. 1997; 99 (7): 1472-7. 20(1); 12 (11.
20. Romani S, Azimzadeh P, Mohebbi SR, Kazemian S, Almasi S, Naghoosi H, et al. Investigation of transforming growth factor-β1 gene polymorphisms among Iranian patients with chronic hepatitis C. Hepatitis monthly. 2011; 11 (11): 901.
21. Akahoshi M, Nakashima H, Miyake K, Inoue Y, Shimizu S, Tanaka Y, et al. Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis. Human genetics. 2003; 112 (3): 237-43.
22. Takahashi N, Akahoshi M, Matsuda A, Ebe K, Inomata N, Obara K, et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. Human molecular genetics. 2005; 14 (21): 3149-59.
23. Esteves LM, Bulhões SM, Branco CC, Mota FM, Paiva C, Cabral R, et al. Human Leptospirosis: Seroreactivity and Genetic Susceptibility in the Population of São Miguel Island (Azores, Portugal). PloS one. 2014; 9 (9): e108534.
24. Namkung JH, Lee JE, Kim E, Kim S, Kim S, Shin ES, et al. Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rβ1 and β2) genes and gene-gene interactions with atopic dermatitis in Koreans. Journal of Dermatological Science. 2010; 57 (3): 199-206.
25. Takahashi N, Akahoshi M, Matsuda A, Ebe K, Inomata N, Obara K, et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. Hum Mol Genet. 2005; 14 (21): 3149-59